IP Library Granted Patent US 9,636,403
Granted Patent B2
US 9,636,403 · App. 13/195,194 · Granted May 2, 2017

Composition for the treatment of ear infections and method

Inventors: Rory J Albert (Scottsdale, AZ); Michael R. Blaire (Scottsdale, AZ)
Assignee: Diamondback Drugs of Delaware, L.L.C.
A61K45/06A61K31/4709A61K31/496A61K31/704A61K31/7048A61K31/56
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,636,403
App. No.
13/195,194
Granted
May 2, 2017
Kind
B2
Abstract

A composition for treating ear infections in animals includes an antifungal agent, an antibiotic agent, a steroidal anti-inflammatory agent, and an acid dissolved to form a liquid. The acid aids in keeping the steroidal anti-inflammatory agent in solution, and enhances the bactericidal effect of the composition. The method of preparing such composition includes dissolving the antifungal agent, steroidal anti-inflammatory agent, and acid in dehydrated alcohol, dissolving the antibiotic agent in propylene glycol, combining the two solutions together, heating the combination and then cooling the composition. Several drops of the composition are applied at least twice per day to the affected area of the animal's ear.

Claims (23)

1. A composition for topical treatment of ear infections in animals comprising:

a. an antifungal agent;

b. an antibiotic agent;

c. a steroidal anti-inflammatory agent; and

d. an anhydrous organic acid;

e. liquid dehydrated alcohol; and

f. propylene glycol.

2. The composition of claim 1 wherein said antifungal agent is selected from the group of antifungal agents consisting of polyenes, azoles, allylamines, morpholines, antimetabolites, and combinations thereof.

3. The composition of claim 1 wherein said antifungal agent is a topical antifungal agent.

4. The composition of claim 1 wherein said antifungal agent is selected from the group of antifungal agents consisting of amphotericin, nystatin, fluconazole, itraconazole, clotrimazole, ketoconazole, terbinafine, 5-fluorocytosine, and combinations thereof.

5. The composition of claim 1 wherein said antifungal agent is present in a concentration of approximately 5 to 50 grams per liter of said composition.

6. The composition of claim 1 wherein said antibiotic agent is selected from the group consisting of ofloxacin, ciprofloxacin, neomycin, polymixin B, enrofloxacin, marbofloxacin, orbofloxacin, and combinations thereof.

7. The composition of claim 1 wherein said antibiotic agent is present in a concentration of approximately 0.5 to 5 grams per liter of said composition.

8. The composition of claim 1 wherein said steroidal anti-inflammatory agent is selected from the group of steroidal anti-inflammatory agents consisting of triamcinolone, betamethesone, hydrocortisone, dexamethasone, and combinations thereof.

9. The composition of claim 1 wherein said steroidal anti-inflammatory agent is present in a concentration of approximately 0.25 to 2.5 grams per liter of said composition.

10. The composition of claim 1 wherein said anhydrous organic acid is selected from the group of acids consisting of citric acid, ascorbic acid, glycolic acid, tartaric acid, and combinations thereof.

11. The composition of claim 1 wherein said anhydrous organic acid is present in a concentration of at least approximately 3 grams per liter of said composition.

12. The composition of claim 1 wherein said composition is homogeneous.

13. The composition of claim 1 wherein

a. the antifungal agent includes ketoconazole;

b. the antibiotic agent includes ofloxacin;

c. the steroidal anti-inflammatory agent includes triamcinolone diacetate; and

d. the anhydrous organic acid includes citric acid.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Dec 24, 2025
From: NATIXIS, NEW YORK BRANCH
To: WEDGEWOOD PHARMACY, LLC (F/K/A WEDGEWOOD VILLAGE PHARMACY, LLC); WILDLIFE LABORATORIES, LLC
Reel/Frame 073309/0637 →
RELEASE OF SECURITY INTEREST Recorded Dec 24, 2025
From: NATIXIS, NEW YORK BRANCH
To: WEDGEWOOD PHARMACY, LLC (F/K/A WEDGEWOOD VILLAGE PHARMACY, LLC); WILDLIFE LABORATORIES, LLC
Reel/Frame 073309/0617 →
SECURITY INTEREST Recorded Dec 23, 2025
From: WILDLIFE LABORATORIES, LLC; WEDGEWOOD PHARMACY LLC; SR VETERINARY TECHNOLOGIES, LLC
To: TCG SENIOR FUNDING, L.L.C.
Reel/Frame 073307/0883 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS RECORDED AT R/F 055804/0377 Recorded Jul 8, 2025
From: MACQUARIE CAPITAL FUNDING LLC
To: NATIXIS, NEW YORK BRANCH
Reel/Frame 071842/0563 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS RECORDED AT R/F 055804/0396 Recorded Jul 8, 2025
From: MACQUARIE CAPITAL FUNDING LLC
To: NATIXIS, NEW YORK BRANCH
Reel/Frame 071842/0569 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2025
From: WEDGEWOOD VILLAGE PHARMACY, LLC
To: SR VETERINARY TECHNOLOGIES, LLC
Reel/Frame 070196/0839 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2025
From: ALBERT, RORY J.; BLAIRE, MICHAEL R.
To: DIAMONDBACK DRUGS OF DELAWARE, L.L.C.
Reel/Frame 069768/0505 →
RELEASE OF SECURITY INTEREST Recorded Apr 7, 2021
From: MARANON CAPITAL, L.P.
To: WEDGEWOOD VILLAGE PHARMACY, LLC
Reel/Frame 055856/0829 →
SECURITY INTEREST Recorded Apr 2, 2021
From: WEDGEWOOD VILLAGE PHARMACY, LLC
To: MACQUARIE CAPITAL FUNDING LLC, AS COLLATERAL AGENT
Reel/Frame 055804/0396 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE CONVEYING PARTY AND THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 046400 FRAME: 0230. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 7, 2020
From: WEDGEWOOD VILLAGE PHARMACY, LLC
To: MARANON CAPITAL, L.P., AS AGENT
Reel/Frame 053144/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2018
From: DIAMONDBACK DRUGS OF DELAWARE, L.L.C.
To: WEDGEWOOD VILLAGE PHARMACY, LLC
Reel/Frame 046582/0164 →
SECURITY INTEREST Recorded Jul 19, 2018
From: MARANON CAPITAL, L.P., AS AGENT
To: WEDGEWOOD VILLAGE PHARMACY, LLC
Reel/Frame 046400/0230 →
Continuity (2)
Division 10830548 · Apr 23, 2004
Related Publication 20110281833A1 · Nov 17, 2011